30 Years of Innovation: Philip Morris International's Transformation Journey

Oct.12.2024
PMI showcases 30-year innovation journey and successful smoke-free transformation in new video on Linkedin, leading to upcoming special event.

On October 11th, the official account of Philip Morris International (PMI) posted a video on the social platform LinkedIn, reviewing the company's 30-year history of innovation and showcasing its achievements in driving the transition to smoke-free products over the past 10 years.


In the video, a group of PMI executives led by CEO André Calantzopoulos stated, "If we don't do it, no one will start. The process is not easy, and it requires a lot of time and collective effort from the company as a whole." The video succinctly outlines the company's transformation from "burning" to "smoke-free": "We realized the potential of technology, and that moment was exhilarating. They came up with the genius idea of eliminating combustion, so smoke-free is the answer to the problem.


Executives stated, "Disrupting our core business requires great courage. But the direction that has already been determined is that smoke-free is the only way forward in the future.


They reviewed the difficult decisions made during the transition: "Despite voices from the outside questioning whether this could be the end of Philip Morris, we still firmly embarked on this journey. I believe we made the right choice.


In addition, PMI will launch a special program on October 17 at 2:00 PM Central European Time to review the journey of smoke-free transformation and invite experts to discuss how to drive industry change through innovation.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Congress Calls on FDA to Allocate at Least $200 Million for ENDS Enforcement, Multi-Agency Task Force to Target Illegal e-Cigarette Imports. IKE Tech and Ispire Utilize Blockchain and Age Verification Technology to Support Regulation, Submit Chips as Part
Congress Calls on FDA to Allocate at Least $200 Million for ENDS Enforcement, Multi-Agency Task Force to Target Illegal e-Cigarette Imports. IKE Tech and Ispire Utilize Blockchain and Age Verification Technology to Support Regulation, Submit Chips as Part
Congress demands FDA allocate at least $200 million for ENDS enforcement; multi-agency task force to combat illegal e-cigarette imports.
Nov.18 by 2FIRSTS.ai
PMI Launches VEEV E-Cigarette in South Africa, Expanding Access to Smoke-Free Alternatives
PMI Launches VEEV E-Cigarette in South Africa, Expanding Access to Smoke-Free Alternatives
Philip Morris International's South Africa branch launches e-cigarette product Veev, making South Africa one of 20 countries with PMI's smoke-free products.
Oct.13 by 2FIRSTS.ai
South Korea Publishes List of Major Tax Delinquents: Vape Wholesaler Owes Over USD 15.5 Million
South Korea Publishes List of Major Tax Delinquents: Vape Wholesaler Owes Over USD 15.5 Million
The Korea Customs Service (KCS) has released a list of 236 habitual and large-scale customs tax delinquents with total unpaid taxes amounting to approximately USD 917 million. Among them, a vape wholesaler tops the individual list, owing about USD 15.57 million, while another vape-related company owes roughly USD 12.02 million.
Nov.11 by 2FIRSTS.ai
Russian State Duma Committee supports bill for tobacco and nicotine products market legalization
Russian State Duma Committee supports bill for tobacco and nicotine products market legalization
A bill endorsing a licensing system for tobacco and nicotine products has been recommended in Russia's State Duma.
Nov.14 by 2FIRSTS.ai
South Korea’s Tobacco Law Amendment to Include Synthetic Nicotine, Projected to Add Up to $340 Million in Local Tax Revenue
South Korea’s Tobacco Law Amendment to Include Synthetic Nicotine, Projected to Add Up to $340 Million in Local Tax Revenue
Following the National Assembly’s approval of amendments to the Tobacco Business Act on September 22, redefining tobacco to include synthetic nicotine, the Korea Institute of Local Finance (KILF) estimates that local governments could gain between $37 million and $340 million in additional tax revenue in 2025 from tobacco consumption and local education taxes.
Nov.19 by 2FIRSTS.ai
ceshi1111
ceshi1111
Trusted by industry leaders and innovators, ARAC brings unmatched expertise in Modules 5 & 6, including label and claim development, comprehension testing, human factors/usability, and clinical-behavioral research such as actual use and switching studies. These studies generate the robust, real-world evidence needed to evaluate whether products are “Appropriate for the Protection of Public Health” (APPH) -- including randomized experimental longitudinal, actual use, cohort st
Oct.21